Please login to the form below

Not currently logged in
Email:
Password:

Merrimack

This page shows the latest Merrimack news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack

French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by second-line pancreatic cancer therapy Onivyde. ... The deal includes Onivyde (liposomal irinotecan) and Merrimack's generic version of Doxil (liposomal

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit

  • FDA approves Merrimack's pancreatic cancer drug FDA approves Merrimack's pancreatic cancer drug

    Onivyde improves overall survival rates. The FDA has approved Merrimack's Onivyde for the treatment of advanced pancreatic cancer. ... Biopharmaceutical science company Baxalta has also payed $62.5m to Merrimack as Onviyde enters phase II trials as a

  • Baxter and Merrimack file pancreatic cancer drug in EU Baxter and Merrimack file pancreatic cancer drug in EU

    Baxter and Merrimack Pharma have filed for approval of their pancreatic cancer therapy MM-398 in the EU, a few days after the FDA started a priority review of the drug. ... The FDA has already given the drug priority review status and Merrimack and Baxter

  • Global pancreatic cancer market to treble in value Global pancreatic cancer market to treble in value

    Other drugs marked out by GlobalData as having significant sales potential include Threshold Pharmaceuticals/Merck's TH-302 and Merrimack Pharmaceuticals' MM-398.  .

  • Eastern Europe targeted

    260. PharmaEngine/Merrimack. MM398 in oncology. Licence. 220. CytRx/Orphazyme. Molecular chaperone assets for rare genetic lysosomal diseases.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics